Short Interest in Mural Oncology plc (NASDAQ:MURA) Decreases By 48.0%

Mural Oncology plc (NASDAQ:MURA) was the recipient of a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 341,900 shares, a drop of 48.0% from the May 15th total of 657,900 shares. Based on an average trading volume of 4,570,000 shares, the short-interest ratio is currently 0.1 days. Currently, 2.7% of the shares of the company are sold short.

Analyst Ratings Changes

Several equities analysts have recently commented on MURA shares. HC Wainwright lowered their target price on Mural Oncology from $18.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, March 26th. Jones Trading restated a “hold” rating on shares of Mural Oncology in a research note on Tuesday, March 25th. Morgan Stanley lowered Mural Oncology from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, March 25th. Finally, Raymond James downgraded shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price target for the company. in a report on Tuesday, March 25th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.00.

Institutional Investors Weigh In On Mural Oncology

Several institutional investors have recently bought and sold shares of MURA. Squarepoint Ops LLC lifted its stake in shares of Mural Oncology by 1.4% in the 4th quarter. Squarepoint Ops LLC now owns 175,502 shares of the company’s stock worth $565,000 after acquiring an additional 2,470 shares during the period. Two Sigma Investments LP raised its holdings in Mural Oncology by 12.0% during the fourth quarter. Two Sigma Investments LP now owns 65,150 shares of the company’s stock worth $210,000 after purchasing an additional 6,993 shares in the last quarter. Northern Trust Corp lifted its position in Mural Oncology by 22.0% in the fourth quarter. Northern Trust Corp now owns 39,966 shares of the company’s stock worth $129,000 after purchasing an additional 7,197 shares during the period. Jane Street Group LLC acquired a new stake in Mural Oncology in the fourth quarter worth approximately $68,000. Finally, Armistice Capital LLC boosted its stake in Mural Oncology by 1.3% during the 1st quarter. Armistice Capital LLC now owns 1,722,000 shares of the company’s stock valued at $2,170,000 after purchasing an additional 22,000 shares in the last quarter. Institutional investors and hedge funds own 80.21% of the company’s stock.

Mural Oncology Stock Performance

Shares of MURA traded down $0.01 during mid-day trading on Monday, reaching $2.45. 94,024 shares of the company’s stock traded hands, compared to its average volume of 1,303,905. The business’s 50-day moving average price is $2.44 and its 200-day moving average price is $3.11. The stock has a market capitalization of $42.31 million, a P/E ratio of -0.27 and a beta of 3.36. Mural Oncology has a 12 month low of $0.95 and a 12 month high of $4.74.

Mural Oncology (NASDAQ:MURA) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.12) by $0.19. Equities research analysts anticipate that Mural Oncology will post -7.54 EPS for the current year.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.